

Pfizer Limited

The Capital, 1802 / 1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel:+91 22 6693 2000 Fax:+91 22 2654 0274

July 12, 2017

The Corporate Relationship Dept. BSE Limited 1st Floor, P.J.Towers Dalal Street, Fort Mumbai - 400 001 Scrip Code: 500680 The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Scrip Symbol: PFIZER

Dear Sirs,

<u>Sub</u>: <u>Quarterly Statement of Investor Complaints - Regulation 13 of the SEBI (LODR)</u>
<u>Regulations, 2015</u>

In compliance with Regulation 13 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith a statement for the quarter ended June 30, 2017, giving number of investor complaints pending at the beginning of the quarter, those received during the quarter, disposed of during the quarter and those remaining unresolved if any, at the end of the quarter.

Request you to take the same on record.

Thanking you,

Yours truly,

For Pfizer Limited

Praject Nair

Company Secretary

Encl: A/a

CIN: L24231MH1950PLC008311

contactus.india@pfizer.com

www.pfizerindia.com



Pfizer Limited

The Capital, 1802 / 1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel: +91 22 6693 2000 Fax: +91 22 2654 0274

Statement for the quarter ended June 30, 2017, under Regulation 13 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Particulars	Number
1.	Investor Complaints pending at the beginning of the quarter	Nil
2.	Investor complaints received during the quarter	24
3.	Investor complaints disposed of during the quarter	24
4.	Investor complaints remained unresolved at the end of the quarter	Nil

For Pfizer Limited

Prajeet Nair

Company Secretary

Date: July 12, 2017

CIN: L24231MH1950PLC008311

contactus.india@pfizer.com

www.pfizerindia.com